MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

Erasca Inc

Затворен

1.41 2.17

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.35

Максимум

1.45

Ключови измерители

By Trading Economics

Приходи

-1M

-32M

EPS

-0.11

Служители

103

EBITDA

1.5M

-35M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+259.71% upside

Дивиденти

By Dow Jones

Следващи печалби

6.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-62M

351M

Предишно отваряне

-0.76

Предишно затваряне

1.41

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

Erasca Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.04.2025 г., 23:27 ч. UTC

Топ новини

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- 2nd Update

28.04.2025 г., 23:07 ч. UTC

Топ новини

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- Update

28.04.2025 г., 23:03 ч. UTC

Печалби

Waste Management 1Q Profit Falls, Revenue Misses Estimates

28.04.2025 г., 23:47 ч. UTC

Пазарно говорене

Gold Edges Lower as Traders Assess Mixed Signals From Treasury Secretary Bessent -- Market Talk

28.04.2025 г., 23:17 ч. UTC

Печалби

Jiangxi Copper 1Q Rev CNY111.61B Vs. CNY122.52B >0358.HK

28.04.2025 г., 23:17 ч. UTC

Печалби

Jiangxi Copper 1Q Net CNY1.95B Vs. Net CNY1.71B >0358.HK

28.04.2025 г., 23:13 ч. UTC

Печалби

China Merchants Securities: Higher Interest Income, Fee Income Also Aided 1Q Results>600999.SH

28.04.2025 г., 23:13 ч. UTC

Печалби

China Merchants Securities 1Q Rev CNY4.71B Vs. CNY4.30B >600999.SH

28.04.2025 г., 23:13 ч. UTC

Печалби

China Merchants Securities: Gains From Investments in Financial Instruments Supported Results >600999.SH

28.04.2025 г., 23:13 ч. UTC

Печалби

China Merchants Securities 1Q Net CNY2.31B Vs. Net CNY2.16B >600999.SH

28.04.2025 г., 23:08 ч. UTC

Печалби

China Longyuan Power: 1Q Power Generation Declined 4.42% on Year>0916.HK

28.04.2025 г., 23:08 ч. UTC

Печалби

China Longyuan Power 1H Rev CNY8.14B Vs. CNY8.07B >0916.HK

28.04.2025 г., 23:08 ч. UTC

Печалби

China Longyuan Power 1H Net CNY1.98B Vs. Net CNY2.53B >0916.HK

28.04.2025 г., 23:04 ч. UTC

Печалби

Huaneng Power: 1Q Net Was Mainly Driven By Decline in Domestic Fuel Costs >0902.HK

28.04.2025 г., 23:04 ч. UTC

Печалби

Huaneng Power: Decrease in Electricity Tariffs Weighed on Rev >0902.HK

28.04.2025 г., 23:04 ч. UTC

Печалби

Huaneng Power 1Q Rev CNY60.33B ; Down 7.7% on Year>0902.HK

28.04.2025 г., 23:04 ч. UTC

Печалби

Huaneng Power 1Q Net CNY4.97B; up 8.2% on Year >0902.HK

28.04.2025 г., 23:00 ч. UTC

Печалби

Jiangsu Expressway 1Q Rev CNY4.78B Vs. CNY3.47B >0177.HK

28.04.2025 г., 23:00 ч. UTC

Печалби

Jiangsu Expressway: 1Q Rev Rose Due to Increase in Road Construction Projects >0177.HK

28.04.2025 г., 23:00 ч. UTC

Печалби

Jiangsu Expressway: Decline in Investment Income, Fall in Revenue Post Asset Disposal Weighed on 1Q Net >0177.HK

28.04.2025 г., 23:00 ч. UTC

Печалби

Jiangsu Expressway 1Q Net CNY1.21B Vs. Net CNY1.25B >0177.HK

28.04.2025 г., 22:57 ч. UTC

Топ новини

Trump Signs Order Requiring Nationwide List of Sanctuary Cities and States -- 8th Update

28.04.2025 г., 22:55 ч. UTC

Печалби

Tsingtao Brewery: Higher Sales Volumes of Beer Supported Results >0168.HK

28.04.2025 г., 22:55 ч. UTC

Печалби

Tsingtao Brewery 1Q Net CNY1.71B Vs. Net CNY1.60B >0168.HK

28.04.2025 г., 22:55 ч. UTC

Печалби

Tsingtao Brewery 1Q Rev CNY10.45B Vs. CNY10.15B >0168.HK

28.04.2025 г., 22:52 ч. UTC

Печалби

S.F. Holding: Results Supported by Higher Contributions From Logistics Business >002352.SZ

28.04.2025 г., 22:52 ч. UTC

Печалби

S.F. Holding 1Q Net CNY2.23B Vs. Net CNY1.91B >002352.SZ

28.04.2025 г., 22:52 ч. UTC

Печалби

S.F. Holding: Cost Controls Also aided 1Q Results >002352.SZ

28.04.2025 г., 22:52 ч. UTC

Печалби

S.F. Holding 1Q Rev CNY69.85B Vs. CNY65.34B >002352.SZ

28.04.2025 г., 22:46 ч. UTC

Печалби

Shandong Gold Mining: Increase in Selling Price of Gold Supported Results>600547.SH

Сравнение с други в отрасъла

Ценова промяна

Erasca Inc Прогноза

Ценова цел

By TipRanks

259.71% нагоре

12-месечна прогноза

Среден 5 USD  259.71%

Висок 6 USD

Нисък 4 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Erasca Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

5

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

1.1301 / 1.42Подкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Strong Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.